<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ELMO2 — Engulfment Cell Motility 2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ELMO2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Engulfment Cell Motility 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>20q13.12</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/63916" target="_blank">63916</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000034053" target="_blank">ENSG00000124780</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/606421" target="_blank">606421</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9Y5V1" target="_blank">Q9Y5V1</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimer), [ALS](/diseases/als), Stroke</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons, microglia), Spleen, Lung, Kidney, Heart</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ELMO2 — Engulfment Cell Motility 2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ELMO2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Engulfment Cell Motility 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>20q13.12</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/63916" target="_blank">63916</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000034053" target="_blank">ENSG00000124780</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/606421" target="_blank">606421</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9Y5V1" target="_blank">Q9Y5V1</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimer), [ALS](/diseases/als), Stroke</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons, microglia), Spleen, Lung, Kidney, Heart</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
ELMO2 (Engulfment and Cell Motility Protein 2) is a gene located on chromosome 20q13.12 that encodes a scaffolding protein critical for various cellular processes including [phagocytosis](/mechanisms/microglial-phagocytosis), [cell migration](/mechanisms/neuronal-migration), and [actin cytoskeleton dynamics](/mechanisms/actin-dynamics). ELMO2 functions as a molecular adaptor that bridges signaling events with downstream effectors to orchestrate cellular responses essential for immune function and neuronal development[@fairbrother2014].
ELMO2 belongs to the ELMO protein family (ELMO1, ELMO2, ELMO3), which are conserved across mammals and play important roles in [phagocytosis](/entities/phagocytosis), cell adhesion, and [neuronal development](/mechanisms/neuronal-development). In the central nervous system, ELMO2 is particularly important for microglial function—a key player in [neuroinflammation](/mechanisms/neuroinflammation) and the clearance of pathological protein aggregates in [Alzheimer's disease](/diseases/alzheimer) and [Parkinson's disease](/diseases/parkinson)[@bok2019].
The connection between ELMO2 and neurodegeneration has become increasingly apparent as research reveals its roles in microglial phagocytosis, protein aggregate clearance, and neuronal survival. These functions position ELMO2 as both a potential therapeutic target and a biomarker for neurodegenerative diseases.
ELMO2 is a ~720 amino acid protein with multiple functional domains:
The protein architecture enables ELMO2 to serve as a molecular scaffold:
ELMO2 has multiple splice variants:
ELMO2 is a critical regulator of phagocytosis[@fairbrother2014]:
ELMO2 coordinates cell motility[@mak2018]:
ELMO2 regulates actin through multiple mechanisms:
ELMO2 participates in:
ELMO2 plays significant roles in [Alzheimer's disease](/diseases/alzheimer) pathogenesis[@chen2018]:
In [Parkinson's disease](/diseases/parkinson), ELMO2 has distinct roles[@kim2020]:
ELMO2 in ALS[@diseases/als]:
ELMO2 contributes to:
The ELMO-Dock180/220 complex is the primary signaling pathway[@fairbrother2014]:
Phagocytic signal → ELMO2 → Dock180 → Rac1 → Actin polymerization
Components:
ELMO2 is modulated by:
ELMO2 interacts with:
ELMO2 connects to:
ELMO2 influences microglial polarization:
ELMO2 enhances microglial phagocytosis:
Several strategies are being explored[@ghosh2017]:
| Approach | Status | Description |
|----------|--------|-------------|
| Small molecule activators | Research | Enhance phagocytosis |
| Gene therapy | Preclinical | Increase ELMO2 expression |
| Peptide inhibitors | Discovery | Modulate ELMO2-Dock interaction |
| Microglial modulation | Research | Indirect targeting |
ELMO2 as a biomarker:
ELMO2 studies in models:
The formation of the ELMO-Dock180 complex represents a critical signaling hub in cellular physiology. This complex functions as a bipartite guanine nucleotide exchange factor (GEF) that activates the small GTPase Rac1. The molecular mechanism involves precise protein-protein interactions and conformational changes that enable efficient signal transduction from membrane receptors to the actin cytoskeleton.
The assembly of the ELMO-Dock180 complex occurs through multiple interaction interfaces. ELMO2 contains multiple domains that mediate distinct protein interactions:
This modular architecture allows ELMO2 to integrate multiple cellular signals and coordinate appropriate cellular responses. The complex formation is regulated by phosphorylation events, with AKT-mediated phosphorylation of ELMO2 enhancing complex formation and Rac1 activation.
Phosphoinositide metabolism plays a crucial role in regulating ELMO2 function:
PI3K-dependent regulation: Class I PI3Ks generate PI3P and PI(3,4,5)P3 at cellular membranes, creating localized signaling platforms where ELMO2 can be recruited and activated. The PH domain of ELMO2 binds specifically to these phosphoinositides, targeting the protein to sites of active signaling.
PTEN antagonism: The lipid phosphatase PTEN counterbalances PI3K activity by dephosphorylating PIP3. This creates a dynamic equilibrium that controls the spatial and temporal patterns of ELMO2 membrane recruitment and activation.
Phosphoinositide effects on phagocytosis: The localized generation of PI3P at phagosomal membranes is essential for ELMO2 recruitment and the actin remodeling required for particle engulfment. Disruption of this process impairs phagocytic capacity.
ELMO2 interfaces with multiple cytoskeletal regulatory systems:
WAVE complex activation: Following Rac1 activation, the WAVE regulatory complex (WAVE1, WAVE2, WAVE3) is recruited to the leading edge of migrating cells. This complex then activates the Arp2/3 complex, which nucleates new actin filaments and drives lamellipodia formation.
Formin pathway: ELMO2-Dock180-activated Rac1 can also signal to formin family proteins, which mediate the elongation of unbranched actin filaments. This provides complementary actin polymerization activity to the Arp2/3-driven branched network.
Myosin regulation: ELMO2 signaling affects myosin II activity through effects on RhoA family GTPases. This influences contractile processes essential for cell migration and phagocytosis.
During brain development, ELMO2 plays essential roles in neuronal positioning and circuit formation:
Neuronal migration: Newborn neurons must migrate from their birthplace to their final position in the developing brain. ELMO2-mediated actin remodeling supports the amoeboid-like movement of migrating neurons along radial glial guides. The protein is particularly important for cortical neuron migration, where its loss leads to neuronal positioning defects.
Axon guidance: Growing axons rely on ELMO2 for proper pathfinding. The protein localizes to growth cones, where it coordinates actin dynamics in response to guidance cues. Netrin, slit, and semaphorin signaling pathways all engage ELMO2-dependent mechanisms for repulsive and attractive guidance.
Dendrite morphogenesis: Post-migration, neurons extend dendrites to form synaptic connections. ELMO2 contributes to dendritic branching and spine formation, with implications for circuit refinement.
ELMO2 continues to function in mature neurons at synapses:
Synaptic vesicle dynamics: While primarily studied in non-neuronal cells, evidence suggests ELMO2 participates in synaptic vesicle cycling. The protein may modulate actin at synaptic terminals, affecting vesicle release and retrieval.
Postsynaptic structure: Dendritic spines, the postsynaptic compartments of excitatory synapses, require actin remodeling for their formation and plasticity. ELMO2 contributes to spine morphogenesis through local actin polymerization.
Synaptic plasticity: Activity-dependent changes in synaptic strength involve structural remodeling of dendritic spines. ELMO2-mediated actin dynamics support these structural changes during long-term potentiation (LTP) and long-term depression (LTD).
Aging affects ELMO2 expression and function in ways that may contribute to neurodegeneration:
Expression decline: ELMO2 expression decreases in the aging brain, particularly in microglia. This reduction impairs microglial phagocytic capacity, allowing accumulated cellular debris and protein aggregates to persist.
Signal transduction deficits: Age-related changes in PI3K signaling reduce ELMO2 membrane recruitment and activation. This compounds the effects of reduced expression.
Cellular senescence: Senescent microglia show altered ELMO2 regulation, contributing to the pro-inflammatory senescence-associated secretory phenotype (SASP).
Alzheimer's Disease: In AD, ELMO2 dysfunction contributes to impaired amyloid-beta clearance. Microglial phagocytosis of Aβ plaques requires ELMO2-Dock180-Rac1 signaling, and reduced ELMO2 function in aged microglia compounds this deficit. Additionally, ELMO2 variants have been associated with AD risk in GWAS studies.
Parkinson's Disease: The specific vulnerability of dopaminergic neurons in PD relates to their interactions with surrounding microglia. ELMO2-mediated phagocytic clearance of alpha-synuclein aggregates is protective, but this function declines with age and in PD.
Multiple Sclerosis: While not a primary neurodegenerative disease, MS involves similar microglial dysfunction. ELMO2's role in phagocytosis may be relevant to lesion dynamics.
Research on ELMO2 employs various genetic approaches:
Knockout strategies: Complete Elmo2 knockout mice are embryonic lethal, necessitating conditional knockouts for brain-specific studies. The phenotype reveals roles in development and immune function.
Knockdown approaches: siRNA and shRNA-mediated knockdown in cell lines enable rapid functional studies. CRISPR-based knockout provides more complete gene disruption.
Transgenic overexpression: AAV-mediated ELMO2 overexpression in the brain enables gain-of-function studies and therapeutic proof-of-concept experiments.
Key biochemical techniques for ELMO2 study include:
Co-immunoprecipitation: Identifying protein-protein interactions through antibody-based capture
GST pull-down assays: Recombinant protein interactions using tagged constructs
Phosphorylation analysis: Western blotting with phospho-specific antibodies to examine regulatory modifications
Lipid binding assays: Testing PH domain binding to phosphoinositides using lipid strip or liposome assays
Visualization of ELMO2 function employs:
Live-cell microscopy: Time-lapse imaging of fluorescently tagged ELMO2 during phagocytosis or migration
Super-resolution microscopy: STED and SIM imaging to resolve ELMO2 localization at nanoscale resolution
FRAP analysis: Fluorescence recovery after photobleaching to measure protein dynamics
Electron microscopy: Ultrastructural analysis of phagocytic structures
Pharmaceutical approaches to target ELMO2 include:
Activators: Compounds that enhance ELMO2-Dock180 complex formation or activity could boost microglial phagocytosis. Screenings have identified candidate molecules that upregulate ELMO2 expression.
Inhibitors: In contexts where excessive phagocytosis contributes to pathology, inhibitors may be beneficial. Peptide inhibitors targeting the ELMO-Dock interaction are under development.
Delivery challenges: Achieving adequate brain penetration remains a significant hurdle. AAV-mediated gene delivery shows promise in preclinical models.
Approaches beyond small molecules include:
Microglial replacement: Stem cell-derived microglia with enhanced ELMO2 function could be transplanted. This approach is in early experimental stages.
Gene therapy: AAV vectors encoding ELMO2 under microglial promoters enable targeted expression. Clinical translation requires further development.
Combination strategies: ELMO2-targeted approaches may synergize with other interventions like anti-amyloid antibodies or metabolic modulators.
ELMO2 has biomarker potential in neurodegeneration:
Blood-based markers: ELMO2 expression in peripheral blood mononuclear cells correlates with disease state. This enables less invasive sampling compared to CSF or brain tissue.
CSF measurements: Cerebrospinal fluid ELMO2 levels may reflect microglial activation status in CNS diseases.
Genetic markers: ELMO2 polymorphisms associated with disease risk enable identification of at-risk individuals.
ELMO2 levels may serve as pharmacodynamic markers:
Key questions driving the field include:
New tools enabling progress include: